bimekizumab

UCB’s Bimzelx wins FDA nod for plaque psoriasis

Bimzelx, a potential blockbuster for psoriasis, clears FDA approval after resolving manufacturing issues

Anika Sharma

UCB’s long-awaited FDA approval for its psoriasis therapy, Bimzelx (bimekizumab), has finally arrived, ending a journey marked by manufacturing setbacks. ...

bimekizumab fda approval, ucb plaque psoriasis drug, bimekizumab review extension, ucb bimekizumab manufacturing, bimekizumab efficacy and safety, bimekizumab european commission approval, bimekizumab il-17 inhibitor

UCB’s psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay

Anika Sharma

After facing delays related to manufacturing issues, UCB’s psoriasis medication, bimekizumab, is awaiting the next steps in its FDA review ...